bioRxivMicrobiologyPreprint
Local albumin excess exacerbates Candida albicans-induced inflammasome activation underlying the immunopathology of vulvovaginal candidiasis.
Sophie AustermeieriD, Axel DietschmanniD, Gianluca Vascelli, Kar On ChengiD, Sophia U J HitzleriD, Kira S. Skurk, Stefanie WestermanniD, Dolly E. MontañoiD, Martin JaegeriD, Nadja Jablonowski, Stephanie Wisgott, Osama Elshafee, Chiara BrachelenteiD, Dennis Marinus de GraafiD, Tomasz Próchnicki, Eicke LatziD, Stefan WirtziD, Christoph BeckeriD, Giorgia RengaiD, Vasileios OikonomouiD, Bernhard HubeiD, Gilbert G.G. DondersiD, Marina G. PekmezoviciD, Teresa ZelanteiD, Mark S. GresnigtiD
Abstract
Vulvovaginal candidiasis (VVC) is a mucosal yeast infection where symptoms are driven by inflammatory responses. The onset of VVC is instigated by the yeast Candida albicans, but the underlying causes of disease-driving hyperinflammation remains incompletely resolved. We found that vaginal albumin concentrations are higher in women with recurrent VVC and during VVC in mice. These albumin levels correlated with inflammatory cytokines in vaginal lavages. While the abundance of this serum protein in the vagina can represent a hallmark of inflammation-induced vascular permeability, we reveal molecular mechanisms by which albumin also drives inflammation. It increased NLRP3 inflammasome activation in human macrophages elicited by C. albicans. Albumin induced fungal adaptations that increased resistance to macrophage-mediated clearance. Further it increased the expression of fungal secreted aspartic protease 1, which we identified as the effector driving inflammasome activation. Moreover, neutrophils show impaired effectivity in clearing C. albicans in presence of albumin. Collectively, vaginal albumin may not only be a consequence of inflammation of the vaginal mucosa, but also can drive hyperinflammatory responses that underlie immunopathology in VVC. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=187 SRC="FIGDIR/small/700771v1_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@f13fd5org.highwire.dtl.DTLVardef@95e58aorg.highwire.dtl.DTLVardef@11104dforg.highwire.dtl.DTLVardef@56e9be_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Recurrent Vulvovaginal Candidiasis; a dynamic interkingdom biofilm disease of Candida and Lactobacillus
E. McKloud, L. Sherry, … G. Ramage·bioRxiv·Feb 12, 2021
- An IL-1, IL-17, and IL-22 cytokine circuit controls vulvovaginal candidiasis independently of estrogen
Bianca M. Coleman, Melissa Erin Cook, … Sarah L. Gaffen·PLoS PathogensPeer-reviewed·May 7, 2026
- Clinical Candida Lactobacillus Isolate Pairs Reveal Distinct Host-Pathogen Interactions in a Vaginal Epithelial Model
Esraa Mubarak Almutawa, Lilyann Novak Frazer, … Riina Rautemaa‐Richardson·bioRxiv·Sep 24, 2025
- Oestrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system
P. Kumwenda, F. Cottier, … R. A. Hall·bioRxiv·Jul 22, 2020
- Vancomycin impairs macrophage fungal killing by disrupting mitochondrial morphology and function
Ebrima Bojang, Lozan Sheriff, … Rebecca A. Drummond·mBioPeer-reviewed·Apr 29, 2026
- Human Als3p Antibodies are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis
P. Uppuluri, S. Singh, … A. S. Ibrahim·bioRxiv·May 17, 2018